Latest News - Clinical Trials

Friday, October 27, 2017 | Clinical Trials, Multiple Sclerosis & Immune Disorders, Phase 3/4 Trials, Research and Publications, Biogen

ECTRIMS: First-in-Class Monoclonal Antibody Shows Promise in Phase 2 Data

Results from the Phase 2 SYNERGY trial suggest that the investigational opicinumab (Biogen) could have an increased clinical effect in patients with relapsing multiple sclerosis (MS) who had the disea…

Read the full story

Tuesday, August 29, 2017 | Business of Medicine, Clinical Trials, Movement Disorders, Research and Publications

AstraZeneca and Takeda Strike $400 Million Development Deal for Investigational Parkinson’s Agent

AstraZeneca and Takeda Pharmaceutical Company Limited will jointly develop and commercialize an investigational alpha-synuclein antibody currently in development for the treatment of Parkinson’s…

Read the full story

Tuesday, March 28, 2017 | Clinical Trials, FDA Approval/Clearance, Multiple Sclerosis & Immune Disorders, Phase 3/4 Trials, Research and Publications, Genentech, Roche

Ocrevus Receives FDA Greenlight for Relapsing, Primary Progressive Forms of Multiple Sclerosis

The FDA has approved Ocrevus (ocrelizumab, Roche/Genentech) for the treatment of both relapsing and primary progressive forms of multiple sclerosis. Ocrelizumab is a humanized antibody that …

Read the full story